SEARCH

SEARCH BY CITATION

References

  • 1
    Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active component of hashish. J Am Chem Soc 1964; 86: 1646-1647.
  • 2
    Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988; 34: 605-613.
  • 3
    Di Marzo V, Petrocellis LD. Plant, synthetic, and endogenous cannabinoids in medicine. Annu Rev Med 2006; 57: 553-574.
  • 4
    Cota D, Tschöp MH, Horvath TL, Levine AS. Cannabinoids, opioids and eating behavior: the molecular face of hedonism? Brain Res Brain Res Rev 2006; 51: 85-107.
  • 5
    Moore SA, Nomikos GG, Dickason-Chesterfield AK, Schober DA, Schaus JM, Ying BP, et al. Identification of a high-affinity binding site involved in the transport of endocannabinoids. Proc Natl Acad Sci U S A 2005; 102: 17852-17857.
  • 6
    Kondo S, Kondo H, Nakane S, Kodaka T, Tokumura A, Waku K, et al. 2-Arachidonoylglycerol, an endogenous cannabinoid receptor agonist: identification as one of the major species of monoacylglycerols in various rat tissues, and evidence for its generation through Ca2+-dependent and -independent mechanisms. FEBS Lett 1998; 429: 152-156.
  • 7
    Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001; 410: 822-825.
  • 8
    Kirkham TC. Endogenous cannabinoids: a new target in the treatment of obesity. Am J Physiol Regul Integr Comp Physiol 2003; 284: R343-R344.
  • 9
    Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994; 350: 240-244.
  • 10
    Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S, for the RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389-1397.
  • 11
    Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, for the RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006; 295: 761-775.
  • 12
    Pagotto U, Pasquali R. The role of the endocannabinoid pathway in metabolism and diabetes. Curr Opin Endocrinol Diabetes 2006; 13: 171-178.
  • 13
    Després J-P, Golay A, Sjöström L, for the Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121-2134.
  • 14
    Woods SC. The endocannabinoid system: mechanisms behind metabolic homeostasis and imbalance. Am J Med 2007; 120: S9-S17.
  • 15
    Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand J-P, et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003; 284: R345-353.
  • 16
    Cota D, Marsicano G, Tschöp M, Grübler Y, Flachskamm C, Schubert M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003; 112: 423-431.
  • 17
    Sipe JC, Waalen J, Gerber A, Beutler E. Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). Int J Obes (Lond) 2005; 29: 755-759.
  • 18
    Jbilo O, Ravinet-Trillou C, Arnone M, Buisson I, Bribes E, Péleraux A, et al. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 2005; 19: 1567-1569.
  • 19
    Liu YL, Connoley IP, Wilson CA, Stock MJ. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes (Lond) 2005; 29: 183-187.
  • 20
    Gary-Bobo M, Elachouri G, Gallas JF, Janiak P, Marini P, Ravinet Trillou C, et al. Rimonabant reduces obesity-associated hepatic steatosis and metabolic syndrome features in obese Zucker fa/fa rat. HEPATOLOGY 2007; 46: 122-129.
  • 21
    Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Bátkai S, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005; 115: 1298-1305.
  • 22
    Horvath TL. The unfolding cannabinoid story on energy homeostasis: central or peripheral site of action? Int J Obes (Lond) 2006;(30 Suppl 1): S30-S32.